KEYNOTE SPEAKER

Human Derived Biomaterials and Cells for Tissue Regeneration/Engineering

Prof. Heinz Redl
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austria

Abstract

Plasma derived fibrin matrix is one of the most versatile biomaterials for tissue engineering and regenerative medicine. Being involved in a > 30 year development we can demonstrate advantages and limitations, application techniques and its special use for growth factor and cell delivery as well as a gene activated matrix.
Another goal in our group is to use „medical garbage“ for regenerative purposes. Therefore we use cells from liposuction, from umbilical cord and placenta derived (PD) – substances (e.g. collagen) and PD structures (e.g. amnion) as well as PD cells (e.g. amnion MSC). “Living” Amnion is used either directly (cryopreserved) using a clinically approved process, e.g. for wound healing and antifibrosis or in a new process that the stem cells residing on and in amnion (“sessile” cells) are differentiated in toto (osteo, chondrogenic direction).
Isolated stem cells are cultured with platelet derived factors (from outdated platelets) to avoid animal products and used directly or pre-differentiated, in autologous or allogeneic fashion. Allogeneic is possible, because the mesenchymal stem cells have minor antigenicity and in addition immunosuppressive properties.
This talk should give an overview about the use of above mentioned procedures within the Austrian Cluster for Tissue Regeneration.

Biography of the Keynote Speaker

Heinz Redl, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria; Austrian Cluster for Tissue Regeneration, Vienna, Austria; Red Cross Blood Transfusion Service of Upper Austria, Linz, Austria

Prof. Heinz Redl is head of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, and Associate Professor at the Vienna University of Technology. He is coordinator of the Austrian Cluster for Tissue Regeneration (together with the Medical University Vienna) with 5 branches – bone, cartilage, peripheral nerve, soft tissue (woundhealing) and imaging. He is CEO of Trauma Care Consult (a non-profit). Dr. Redl specializes in biochemistry and ultrastructural research. His research interests are in the areas of: diagnostic and therapeutic measures in trauma care; fibrin matrix for cells and growth factors and its application methods; adult STEM cells (including iPS); preclinical models for musculoskeletal/ neuro area; imaging techniques for TERM; and translational approaches. He is book editor and member of multiple editorial boards. His publications include more than 360 PubMed cited publications and 10 patents (mainly in the fibrin matrix (sealant) field). Dr. Redl is invited speaker and organizer at various international conferences and meetings.